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Abstract 
Background: Anti-malarial drugs are the major focus in the prevention and treatment of malaria. Artemisinin-based 
combination therapy (ACT) is the WHO recommended first-line treatment for Plasmodium falciparum malaria across 
the endemic world. Also ACT is increasingly relied upon in treating Plasmodium vivax malaria where chloroquine 
is failing. The emergence of artemisinin drug-resistant parasites is a serious threat faced by global malaria control 
programmes. Therefore, the success of treatment and intervention strategies is highly pegged on understanding the 
genetic basis of resistance.
Methods: Here, resistance in P. falciparum was generated in vitro for artemisinin to produce levels above clinically 
relevant concentrations in vivo, and the molecular haplotypes investigated. Genomic DNA was extracted using the 
QIAamp mini DNA kit. DNA sequences of Pfk13, Pfcrt and Pfmdr1 genes were amplified by PCR and the amplicons 
were successfully sequenced. Single nucleotide polymorphisms were traced by standard bidirectional sequencing 
and reading the transcripts against wild-type sequences in Codon code Aligner Version 5.1 and NCBI blast.
Results: Exposure of parasite strains D6 and W2 to artemisinin resulted in a decrease in parasite susceptibility to 
artemisinin (W2 and D6) and lumefantrine (D6 only). The parasites exhibited elevated IC50s to multiple artemisinins, 
with >twofold resistance to artemisinin; however, the resistance index obtained with standard methods was notice-
ably less than expected for parasite lines recovered from 50 µg/ml 48 h drug pressure. The change in parasite suscep-
tibility was associated with Pfmdr-185K mutation, a mutation never reported before. The Pfcrt-CVMNK genotype (Pfcrt 
codons 72–76) was retained and notably, the study did not detect any polymorphisms reported to reduce P. falcipa-
rum susceptibility in vivo in the coding sequences of the Pfk13 gene.
Discussion: This data demonstrate that P. falciparum has the capacity to develop resistance to artemisinin derivatives 
in vitro and that this phenotype is achieved by mutations in Pfmdr1, the genetic changes that are also underpinning 
lumefantrine resistance. This finding is of practical importance, because artemisinin drugs in Kenya are used in combi-
nation with lumefantrine for the treatment of malaria.
Conclusion: Artemisinin resistance phenotype as has been shown in this work, is a decrease in parasites susceptibil-
ity to artemisinin derivatives together with the parasite’s ability to recover from drug-induced dormancy after expo-
sure to drug dosage above the in vivo clinical concentrations. The study surmises that Pfmdr1 may play a role in the 
anti-malarial activity of artemisinin.
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Background
Malaria is one of the most serious life-threatening pro-
tozoan diseases, classically identified by paroxysm, fever, 
and flu-like symptoms recurring in 48- or 72-h cycles. 
The World Health Organization (WHO) recommends 
artemisinin-based combination therapy (ACT) as the 
first-line treatment for falciparum malaria in all endemic 
regions [1]. There is already evidence of reduced sus-
ceptibility of P. falciparum to artemisinin derivatives in 
Southeast Asia which is manifested by the delayed par-
asite clearance times in  vivo [2, 3]. WHO has launched 
an action plan to stop possibly emerging resistance at an 
early stage so as to protect ACT [4].
The P. falciparum multidrug resistance 1 gene (Pfmdr1), 
P. falciparum chloroquine resistance transporter gene 
(Pfcrt), and kelch13 propeller region (Pfk13) gene sin-
gle nucleotide polymorphisms (SNPs) are believed to be 
markers of resistance to a great number of anti-malarial 
drugs, including ACT [5, 6].
Increased copy number and sequence variation in 
Pfmdr1 at the amino acid positions N86Y, S1034, N1042 
and D1246Y have been reported to interfere with the par-
asite susceptibility to dihydroartemisinin [7], artemisinin 
[8, 9], mefloquine [10], quinine [8], halofantrine [11], 
piperaquine [9], lumefantrine [12], amodiaquine [13] 
and chloroquine [14]. Recent in vitro work have strongly 
linked Pfmdr1 to drug transportation [15].
The Pfcrt protein has capacity to efflux peptides and 
glutathione [16], and transport anti-malarials besides 
chloroquine [17]. Its codon K76T mutation has been 
linked to the development of chloroquine resistance [18]. 
Pfcrt SNPs have also been found to be associated with 
the in vitro and/or in vivo parasite susceptibility to arte-
misinin [19], lumefantrine [20], quinine [21], mefloquine 
[18] and piperaquine [22].
The Pfk13 SNPs;C580Y, R539T, I543T, and Y493H were 
the four main alleles which were observed to be signifi-
cantly involved in artemisinin resistance out of the 17 
non-synonymous SNPs found in Cambodia [5]. Other 
genes associated with artemisinin resistance include; 
Pfcrt [23], P. falciparum translationally controlled tumor 
protein (Pftctp) gene [24], Pfmdr1, P. falciparum multi-
drug resistance-associated protein-1 (Pfmrp1) [9] and 
ABC transporters [25]. Also there are target proteins; P. 
falciparum calcium adenosine triphosphatase 6 (Pfat-
pase6) [26] and P. falciparum ubiquitin c-terminal hydro-
lase (Pfubcth), the orthologue of P. chabaudi ubiquitin 
protein-1 [27].
The identification of the genetic determinants will be 
cornerstone for understanding the molecular basis of 
artemisinin drug resistance and will, therefore, provide 
basic evidence for molecular surveillance of drug-resist-
ant P. falciparum strains for epidemiological surveys. 
This study reports an assessment of anti-malarial resist-
ance marker polymorphisms in Pfmdr1, Pfcrt, and Pfk13 
genes in chloroquine resistant W2 and chloroquine sen-
sitive D6 lines cultured in presence of artemisinin.
Methods
Study site
The study was carried out at the Centre for Biotech-
nology Research and Development (CBRD) malaria 
laboratory, Kenya Medical Research Institute (KEMRI) 
Headquarters, Nairobi, Kenya.
Parasite cultures
Two P. falciparum laboratory clones, W2 (Indochina) and 
D6 (Sierra Leone) were cultivated by standard methods, 
as described by Trager and Jensen [28] with some modifi-
cations described by Benoit-Vical et al. [29]. Continuous 
routine cultures were maintained at 1–5 % parasitaemia 
in complete medium containing 12.5 % heat inactivated 
human serum (blood type A, AB and O pooled) and in 
O+ human erythrocytes. Haematocrit was adjusted to 
6 % O+ type RBCs of the 5 ml total culture volume. The 
choice of the two parasite lines (D6 and W2) was made 
in the anticipation that different genetic backgrounds of 
the parasites may provide a wider span of genetic deter-
minants during the in  vitro evolution by artemisinin 
selection.
Development of resistant parasite lines
Artemisinin resistance was induced in P. falciparum W2 
and D6 lines as described by Oduola et al. [30]. Plasmo-
dium falciparum W2 and D6 lines were cultured under 
increasing artemisinin pressure in stepwise increments 
over 450 days. The starting concentration of artemisinin 
was 10  µg/ml for the two parasite clones (W2 and D6). 
Then, increments were in escalations of 10, 20, 30, 40 
and 50  µg/ml, with an exposure time of 48  h at each 
increment.
The drug pressure cycle started with the addition of 
artemisinin to asynchronous cultures with 4–8 % parasi-
taemia. The 12.5 % human-serum-supplemented growth 
medium (RPMI Medium 1640; Gibco®), with or with-
out artemisinin, was changed after 24 h. The artemisinin 
pressure was removed after 48 h, the time at which para-
site morphology was degraded and growth was signifi-
cantly reduced. The medium containing artemisinin was 
discarded and parasites washed twice with drug free 
wash media. Then, drug-free culture medium supple-
mented with 12.5 % human-serum was added to cultures, 
which were incubated at 37 °C until parasite growth and 
morphology became normal.
A parasite was considered “tolerant” to a particu-
lar artemisinin concentration when the recovery phase 
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occurred within 48  h. The artemisinin exposure time 
was between 42 and 173 days so as to reduce the recov-
ery time to below 48 h for the W2 and D6 lines at each 
increment. This was considered as a cycle of artemisinin 
pressure. At this point, artemisinin pressure was resumed 
with the consecutive higher artemisinin concentration in 
the increment to culture which has attained ≥5 % para-
sitaemia. During adaptation, parasite was frozen and the 
procedure was resumed from the cryopreserved stocks to 
maintain this phenotype.
Bulk culture of W2 cycle 5 culture A at 50 µg/ml arte-
misinin (W2 c5A), D6 cycle 3 culture A at 30 µg/ml arte-
misinin (D6 c3A) and D6 cycle 5 culture A at 50 µg/ml 
artemisinin (D6 c5A) parasites was cloned by limiting 
dilution for 35 days to give W2 cycle 5 sub-culture B (W2 
c5B), D6 cycle 3 sub-culture B (D6 c3B) and D6 cycle 5 
sub-culture B (D6 c5B), respectively. However, W2 cycle 
3 culture A at 30  µg/ml artemisinin (W2 c3A) was not 
cloned. The samples of these cultures were collected 
and stored in extraction buffer for further analysis. Arte-
misinin together with other conventional anti-malarials 
[dihydroartemisinin (DHA), artemisinin (QHS), artesu-
nate (AS), artemether (AM), chloroquine diphosphate 
(CQ), lumefantrine (LUM) and piperaquine phosphate 
(PIP)], susceptibilities were assayed by measuring the 
inhibition of [3H] hypoxanthine uptake in a sterile tech-
nique [31], as described herein.
[3H] hypoxanthine incorporation assays
Plasmodium falciparum growth was determined by 
measuring incorporation of the nucleic acid precursor 
[3H] hypoxanthine in the parasites genomic DNA. Test 
compounds were diluted in DMSO (except CQ; diluted 
in water) and diluted to >0.2 % DMSO. 25 µl of screen-
ing medium was added to each well (except row B) in a 
96-well flat-bottom micro-culture plate (Costar®, Corn-
ing Incorported, NY, USA). Fifty microlitre of dissolved 
compounds, containing four times the highest test con-
centration, were added to wells of row B in duplicates. 
Two times serial drug dilutions were prepared using a 
multichannel pipette. Twenty five microlitre of drug solu-
tion were taken from wells of row B and transferred, after 
mixing, to wells of row C and so forth down to row H 
(a 64-fold range dilution). The 25 µl of diluent removed 
from wells of row H were discarded. Two hundred micro-
litre of infected erythrocytes (1.5  % haematocrit and 
0.5 % parasitaemia) were then added to each well except 
for wells A9–A12, to which, 200  µl of uninfected RBCs 
(diluted in screening medium to 1.5 % haematocrit) were 
added as a negative control.
The plates were incubated at 37 °C in a chamber gassed 
by a medical grade gas mixture of 92  % N2, 3  % O2, 
and 5 % CO2 at 95 % humidity. After a 48-h incubation 
period, 25 µl of [3H] hypoxanthine working solution was 
added by pulsing to each well (0.5 µCi per well).
Plates were incubated for an additional 18  h period 
then frozen at negative 20 °C. After thawing, the content 
of the plates was harvested onto glass-fiber filter mats (A 
1450-421; Perkin Elmer) using a Betaplate cell harvester 
(1295-004 Betaplate; Wallac Perkin Elmer) and dried in 
an oven.
The oven-dried filter mats were drenched in 10  ml of 
scintillation fluid (Beta Scintilla®, Perkin Elmer, Schwer-
zenbach, CH) in a plastic foil (1450-432; Perkin Elmer) 
and the [3H] hypoxanthine incorporation was measured 
in terms of counts per minute (cpm) using a Betaplate 
liquid scintillation counter (1205 Betaplate; Wallac Per-
kin Elmer).
The result of each well was recorded as counts per 
minute and expressed as percentage of the untreated 
(positive) control (wells A1–A8; cultures without test 
compound). The negative control was used for back-
ground subtraction. IC50s (drug concentration at which 
50  % of [3H] hypoxanthine incorporation was inhibited 
compared to drug-free controls) were estimated by linear 
interpolation [32].
Data analysis was done using Graph Pad Prism soft-
ware, version 5 (Graph Pad Software, Inc.), and the con-
centrations of the drugs that inhibited parasite growth by 
50 % (IC50) were obtained by nonlinear regression analy-
sis of the inhibition of uptake values and log-transformed 
concentration values.
Genomic DNA isolation
The genomic DNA was extracted from 1 to 2  ml ali-
quots of parasite cultures by using the QIAamp mini 
DNA kit (Qiagen, Germany) as per the manufacturer’s 
specifications and eluted in 50  µl of AE elution buffer. 
Non-template control samples were obtained by using 
un-parasitized red blood cells in each extraction. The 
untreated parasites (i.e., no drug pressure, W2 and D6) 
samples, cultured for the same period of 450 days, were 
used as the positive controls.
Sequencing of the Pfmdr1, Pfcrt and Pfk13 genes
The Pfmdr1 (PFE1150w), Pfcrt (MAL7P1.27), and Pfk13 
(PlasmoDB identifier PF3D7_1218300) genes were ampli-
fied from genomic DNA using polymerase chain reac-
tion (PCR). The primers used for PCR and sequencing 
of the genes are shown in Table  1. The double-strand 
sequencing of PCR products was performed by Macro-
gen laboratory (Netherlands). Sequences were analysed 
by the BLAST programme in ncbi. Multiple nucleotide 
sequence alignment and analysis of the reported gene 
3D7 in PlasmoDB DB and Pfmdr1, Pfcrt, and Pfk13 
sequenced genes was done using the Codon code Aligner 
Page 4 of 9Njokah et al. Malar J  (2016) 15:381 
version 5.1 and MEGA 6 to identify specific single nucle-
otide polymorphism (SNP) combinations (standard bidi-
rectional sequencing and reading).
Nucleotide sequence accession numbers
The DNA sequences of representative samples showing 
mutant types were submitted to Gen-Bank and assigned 
accession numbers KU236713 and KU236714.
Results
Discontinuous drug pressure generates P. falciparum lines 
tolerant to increased levels artemisinin in vitro
The IC50 values of artemisinin for the parental parasite 
lines W2 and D6 were determined by [3H] hypoxan-
thine incorporation susceptibility assays [31], which were 
2.85  ng/ml for W2 and 3.06  ng/ml for D6 (Table  2). As 
the parasites became adapted to gradually increased con-
centrations of artemisinin, the two lines became increas-
ingly less susceptible to the drugs, artemisinin (QHS), 
dihydroartemisinin (DHA), artesunate (AS) and lume-
fantrine (LMF) (for D6 only), but more susceptible to CQ 
(Table 2).
W2 c5B after W2 was the most tolerant strain pro-
duced from the assay described above, which was treated 
with artemisinin at a level that surpassed what would 
typically be found in plasma of malaria patients treated 
with artemisinin (Fig.  1). This produced W2 parasites 
that tolerated 50 µg/ml artemisinin for 48 h.
The adaptation pattern observed was similar, a marked 
reduction in artemisinin susceptibility when the para-
sites became adapted to 50  µg/ml (Fig.  2), a phenotype 
manifested the selected progenies progressing normally 
through the erythrocytic stages of the lifecycle, with no 
substantial differences in growth from the parental lines 
in the absence of artemisinin pressure.
Resistant phenotype was due to polymorphism in Pfmdr1 
gene
Key polymorphic regions of the Pfmdr1 gene that cov-
ered codons 86 and 184 were sequenced successfully in 
the parental and resistant progenies. Mutations N86Y 
was observed in the parental W2 parasite lines, while 
D6 parasites had “wild-type” Pfmdr1. Interestingly the 
parental parasites and their respective progenies had 
Table 1 Primers used in PCR
Gene ID Chromosome Primers Direction PCR size
Pfcrt MAL7P1.27 5 P1 (5′-gcgcgcgcatggctcacgtttaggtggag-3′) Forward Primary PCR _146 bp
P2 (5′-gggcccggcggatgttacaaaactatagttacc-3′) Reverse
D1 (5′-tgtgctcatgtgtttaaactt-3′) Forward Nested PCR
D2 (5′-caaaactatagttaccaattttg-3′) Reverse
Pfmdr1 PFE1150w 7 Af (5′-tgtatgtgctgtattatcaggaggaac-3′) Forward Primary PCR _560 bp
Ar (5′-aattgtactaaacctatagatactaatgataatattatagg-3′) Reverse
Bf (5′-gatggtaacctcagtatc-3′) Forward Nested PCR
Br (5′-ctcctgataatacagcac-3′) Reverse
Pfk13 PlasmoDB PF3D7_1218300 13 K13-1 (5′-cggagtgaccaaatctggga-3′) Forward Primary PCR 845 bp
K13-4 (5′-gggaatctggtggtaacagc-3′) Reverse
K13-2 (5′-gccaagctgccattcatttg -3′) Forward Nested PCR
K13-3 (5′-gccttgttgaaagaagcaga -3′) Reverse
Table 2 In vitro susceptibility testing of parental and resistant lines to anti-malarial drugs
W2 c5B = W2 P. falciparum line exposed to artemisinin, D6 c5B = D6 P. falciparum line exposed to artemisinin
QHS artemisinin, DHA dihydroartemisinin, CQ chloroquine diphosphate, PIP piperaquine phosphate, AM artemether, AS artesunate, LMF lumefantrine, ED50 50 % 













W2 2.85 ± 0.55 127.66 ± 1.96 64.18 ± 10.18 10.49 ± 0.06 3.92 ± 0.66 0.45 ± 0.16 0.60 ± 0.15
W2 c5B 9.13 ± 0.127 60.63 ± 8.62 51 ± 4.23 10.5 ± 0.27 5.44 ± 0.20 0.94 ± 0.26 2.35 ± 0.65
D6 3.06 ± 0.19 12.67 ± 0.03 44.37 ± 11.69 54.9 ± 3.99 8.74 ± 0.35 1.64 ± 0.45 1.454 ± 0.35
D6 c5B 8.26 ± 0.55 11.67 ± 2.05 55.46 ± 3.4 84.58 ± 1.64 12.26 ± 0.66 4.19 ± 1.03 7.66 ± 0.36
3D7 15.5 ± 0.95 13.36 ± 1.09 55.04 ± 0.81 54.52 ± 5.88 9.68 ± 2.17 2.78 ± 0.14 4.66 ± 0.93
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Y184 codon but I185K mutation was reported as a novel 
polymorphism. The amino acid codons at these positions 
are shown in Table 3.
Codons 72–76 of Pfcrt
The wild-type Pfcrt allele, encoding CVMNK at codons 
72–76 of the crt protein was confirmed as present in both 
D6 (one sample of the one sequenced, D6 isolate) and its 
tolerant progenies (four samples of the four sequenced, 
D6 c3A, D6 c3B, D6 c5A and D6 c5B), but W2 (one sam-
ple of the one sequenced, W2 isolate) and its subsequent 
progenies (three samples of the three sequenced, W2 
c3A, W2 c5A and W2 c5B) harboured the CVIET allele.
Pfk13 propeller
The changes in amino acid sequences at codon C580Y, 
R539T, I543T, and Y493H as has been reported by Ariey 
et al. [5], were not detected in either parent lines W2 and 
D6 or their artemisinin tolerant progenies and all the 
coding sequences were “wild type”.
Discussion
There are several drawbacks to ACT as the current strat-
egy, despite its success over the last decade. The WHO 
[33] currently endorses five combinations artemether-
lumefantrine, dihydroartemisinin–piperaquine phos-
phate, artesunate-amodiaquine, artesunate-mefloquine, 
and artesunate–pyronaridine. ACT is a highly used anti-
malarial, creating a substantial selection advantage for 
parasites to evolve resistance independently with a pre-
cipitous decline in the artemisinin susceptibility.
In 2014, the number of courses treatment using vari-
ous artemisinin-based combinations increased from 
11 million in 2005 to 337 million [34], but the mecha-
nisms by which artemisinin act is still under investiga-
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Fig. 1 Changes in the index of resistance. Changes in the index of 
resistance (ratio of the IC50 for the resistant progeny to the IC50 
for the parental line) to various drugs during the adaptation of the 
P. falciparum lines W2 and D6 to artemisinin. QHS artemisinin, DHA 
dihydroartemisinin, CQ chloroquine diphosphate, PIP piperaquine 
phosphate, AM artemether, AS artesunate, LMF lumefantrine. There 
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D6 W2
Fig. 2 Plasmodium falciparum lines discontinuous artemisinin pres-
sure. W2 and D6 P. falciparum lines were exposed to a discontinuous 
artemisinin pressure up to 50 µg/ml within a period of 450 days
Table 3 Pfmdr1 and Pfcrt allelic types in parental and resistant P. falciparum lines
D6 c3A, D6 c3B, D6 c5A, D6 c5B = D6 P. falciparum line exposed to artemisinin. W2 c3B, W2 c5A, W2 c5B = W2 P. falciparum line exposed to artemisinin
Parasite line Pfmdr1 Amino acid position Pfcrt Amino acid positions
86 184 185 72 73 74 75 76
W2 Y Y I C V I E T
W2 c3B Y Y K C V I E T
W2 c5A Y Y K C V I E T
W2 c5B Y Y K C V I E T
D6 N Y I C V M N K
D6 c3A N Y K C V M N K
D6 c3B N Y K C V M N K
D6 c5A N Y K C V M N K
D6 c5B N Y K C V M N K
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paramount for determining treatment strategies, map-
ping the spread of resistance and guiding elimination 
[27, 35, 36]. For the new tools for resistance surveillance 
to be validated a better understanding of the mecha-
nisms of artemisinin resistance is needed. These tools 
are essential in guiding national treatment policies and 
helping in designing and deploying new drug combi-
nations that may counter the emergence and spread of 
resistance.
In the present study, the discontinuous method of 
inducing resistance/tolerance to artemisinin in W2 and 
D6 lines of P. falciparum was used [30]. In agreement 
with other study [36], the in vitro developed artemisinin-
tolerant parasites could not grow permanently under 
artemisinin pressure. Hence resistance to artemisinin 
is different from resistance to other conventional anti-
malarial drugs, such as amodiaquine. The culmination of 
in vitro resistance as used here in, is the ability for para-
sites to survive pharmacologically relevant exposure of 
artemisinin (levels considered clinically relevant in vivo) 
over many generations and by major increases in the 
IC50. After conducting the [3H] hypoxanthine incorpo-
ration susceptibility assays, it was found that resistant 
parasites showed the greatest tolerance for artemisinin 
(W2 c5B and D6 c5B). The study hypothesized a reduced 
susceptibility to this drug, because it was used to induce 
resistance in these strains. The discontinuous drug pres-
sure selection scheme is supposedly to have been the key 
to success in selecting the tolerant lines [30]. After adapt-
ing, the parasites were able to tolerate as much as 50 µg/
ml of artemisinin for 48  h without noticeable changes 
in growth rate or morphology. The results also showed 
resistant parasites generally had decreased susceptibility 
to artemisinin, but were more susceptible to CQ, which 
is in agreement with other studies [7, 37, 38]. There was 
a significant degree of cross-resistance to various other 
artemisinin derivatives, including artemether, artesu-
nate, and dihydroartemisinin which were not utilized 
in the generation of resistance in those particular lines. 
This highlights that, it is possible to select resistance in a 
drug-sensitive background (D6) African isolate, in antag-
onism to conclusion from other studies in which it was 
stated that multiple resistance phenotypes must pre-exist 
[39, 40].
These artemisinin-tolerant parasites provided a unique 
resource for the study of the artemisinin resistance 
mechanism(s) and modes of action based on analysis 
of SNPs in Pfmdr1, Pfk13 and haplotypes in Pfcrt. The 
rationale for considering using these three genes were (i) 
that a relationship between SNPs in Pfmdr1 and ACT has 
been reported, suggesting that Pfmdr1-N86 or -184F was 
selected in reinfections after artemether-lumefantrine 
treatment; and moreover, Pfcrt-76K and Pfmdr1-N86 
were selected by artemether-lumefantrine in recurrent 
infections [20]. Pfmdr1 and Pfcrt were selected for chlo-
roquine resistance and they also both have been reported 
to be associated with in  vitro reduced susceptibility to 
artesunate and amodiaquine [41]. (ii) Genome associa-
tion studies strongly suggested a locus on P. falciparum 
chromosome 13 gene PF3D7_1343700 (bases 1,724,817–
1,726,997, PlasmoDB 11.1) to artemisinin resistance and 
mutations discovered in the Pfk13 were strongly linked to 
artemisinin resistance [5].
It is well known that Pfmdr1 is associated with drug 
resistance in Asia [7, 38]. Pfmdr1 encode protein of the 
ATP binding cassette (ABC) transporter superfam-
ily encoding P-glycoprotein homologue-1 [42], which 
are localized to the parasite food vacuole membrane or 
plasma membrane and can decrease intracellular drug 
accumulation by pumping out drugs.
SNPs at codons 86, 184, and 1246 of the Pfmdr1 gene 
has been suspected to be the markers of changes in para-
site susceptibility to various drugs, including ACT [43]. 
This shows that monitoring of changes in prevalence of 
SNPs in the Pfmdr1 gene may serve as an early warning 
tool to selection of P. falciparum tolerant/resistant to 
ACT [44].
In the two artemisinin-tolerant parasite lines used in 
the present study, the decrease in parasite susceptibility 
to the drug was associated with substitution of muta-
tion at codon Y184F for I185K. This conforms with other 
studies where sequence variation and increase in copy 
number in Pfmdr1 were reported to interfere with the 
parasite susceptibility to dihydroartemisinin [7] and arte-
misinin [9]. This is because; the mutation at codon Y184F 
was not detected in the two studies. However, other stud-
ies have shown a relationship between SNPs in Pfmdr1 
and ACT drugs, in that Pfmdr1-N86 or -184F was 
selected in reinfections and Pfcrt-K76 and the Pfmdr1-
N86 in recurrent infections after artemether-lumefan-
trine treatment [20].
It is established that ACT can select for particular 
alleles of two genes, Pfmdr1 and Pfcrt, which are firmly 
associated with resistance to the 4-aminoquinolines chlo-
roquine and amodiaquine. The Pfcrt gene that encodes 
a 424-amino acid integral 10 trans-membrane domains 
protein is a transporter present in the parasite digestive 
vacuole membrane.
In this work, it was observed that Pfcrt-CVMNK were 
the favoured haplotypes. This can be attributed to com-
pensatory mutation at C350R in a different study, which 
was shown to explain the seemingly discordant chloro-
quine response in Pfcrt-CVIET haplotype [45]. This may 
suggest the benefit of the two wild-type genes, Pfmdr1-
N86 Y184 and Pfcrt-CVMNK, was enhanced by the pres-
ence of artemisinin.
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Ariey et al. [5] linked artemisinin resistance in P. fal-
ciparum to slow clearance rates in patients which he 
strongly associated with single point mutations in the 
“propeller” domain of the P. falciparum kelch protein 
gene on chromosome 13 (kelch13) (PlasmoDB identifier 
PF3D7_1218300). 17 mutations in the propeller region 
are linked to artemisinin drug resistance. The Pfk13 
gene is well conserved across Plasmodium species and 
is thought to mediate protein–protein interactions [5].
WHO included Pfk13 mutations (Y493H, I543T, R539T, 
C580Y and M476I) in the new working definition for 
suspected artemisinin resistance in August 2014 [46]. 
The present study did not detect any polymorphisms 
reported elsewhere to reduce P. falciparum susceptibil-
ity in vivo in the coding sequences of the Pfk13 gene.
Although it is clear that Pfmdr1 may play a significant 
role in artemisinin resistance, some studies also demon-
strated that changes in susceptibility to mefloquine or 
halofantrine could be achieved without changes in the 
expression level or allelic type of Pfmdr1 [47, 48], sug-
gesting a possible involvement of other genes and/or 
mechanisms of sustaining resistance in these parasites, 
including transient changes in gene expression.
Other work has reported lack of mutations in Pfmdr1 
and Pfcrt in parasites cultured for 5  years under arte-
misinin derivatives in  vitro, and Pfmdr1 amplification 
was not observed. Further, four mutations were dis-
covered in Pfk13 (Y493H, I543T, R539T and C580Y). 
In the same study, 17 single K 13-propeller mutations 
were detected in naturally circulating parasites in Cam-
bodia [5]. However in the present study, there was 
Pfmdr1 novel mutation at codon I185K and no non-syn-
onymous mutations in Pfk13 gene. This difference can 
be attributed to the shorter period (450  days) of arte-
misinin exposure.
Conclusion
ACT is the critical tool for controlling the world’s most 
important parasitic disease; malaria. This necessitates 
research on artemisinin resistance markers for epidemi-
ological surveys in malaria endemic regions. This work 
has demonstrated that resistance to artemisinin can be 
induced in P. falciparum in  vitro. Although long-term 
stability studies at high levels of drug exposure have not 
been completed; this data suggest that stable artemisinin 
tolerance was selected for by multiple pulse exposures 
to drug over time. This is reflected in the substitution of 
Pfmdr1 Y184F mutation for I185K. Clearly, more studies 
are required to identify the mechanism(s) by which resist-
ance to artemisinin emerges and to find molecular genetic 
markers that can be used for epidemiological studies to 
track the possible emergence of artemisinin resistance.
Recommendations
High artemisinin resistant lines should be selected and 
probably to a line which can grow continuously under 
artemisinin pressure. Thereafter, the investigations into 
artemisinin resistance markers mainly targeting the 
implicated genes Pfk13, Pfmdr1 and Pfubcth associated 
with reduction in drug efficacy should be performed. 
Structured studies that mitigate confounding factors 
such as multiple clonal infections in a variety of cross-
ing experiments should be investigated in  vivo. This is 
because in the laboratory, the effect of the mutation is 
determined in only one genetic background but a wide 
variety of backgrounds are found in the field due to 
recombination.
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